Stefania Ferrari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7731276/publications.pdf

Version: 2024-02-01

63	1,653	331259	315357
papers	citations	21 h-index	38 g-index

67	67	67	2477
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Hippo Pathway and YAP/TAZâ€“TEAD Proteinâ€“Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. Journal of Medicinal Chemistry, 2015, 58, 4857-4873.	2.9	141
2	Discovery of potent pteridine reductase inhibitors to guide antiparasite drug development. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1448-1453.	3.3	135
3	2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1. ACS Chemical Biology, 2015, 10, 705-714.	1.6	116
4	Thymidylate Synthase Structure, Function and Implication in Drug Discovery. Current Medicinal Chemistry, 2005, 12, 2241-2258.	1.2	91
5	Proteinâ€“protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E542-9.	3.3	77
6	Virtual Screening Identification of Nonfolate Compounds, Including a CNS Drug, as Antiparasitic Agents Inhibiting Pteridine Reductase. Journal of Medicinal Chemistry, 2011, 54, 211-221.	2.9	68
7	Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resistance Updates, 2015, 23, 20-54.	6.5	57
8	Novel 3â€benzoylâ€2â€piperazinylquinoxaline derivatives as potential antitumor agents. Journal of Heterocyclic Chemistry, 2006, 43, 541-548.	1.4	50
9	Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells. International Journal of Oncology, 2013, 43, 1269-1280.	1.4	47
10	Update on Antifolate Drugs Targets. Current Drug Targets, 2001, 2, 135-166.	1.0	46
11	Homodimeric Enzymes as Drug Targets. Current Medicinal Chemistry, 2010, 17, 826-846.	1.2	45
12	Current and Future Chemotherapy for Chagas Disease. Current Medicinal Chemistry, 2015, 22, 4293-4312.	1.2	45
13	Structure-Based Selectivity Optimization of Piperidineâ€“Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 8318-8329.	2.9	42
14	Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs. Journal of Medicinal Chemistry, 2016, 59, 7598-7616.	2.9	41
15	Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity. Molecules, 2017, 22, 426.	1.7	39
16	Inhibitor Specificity via Protein Dynamics. Chemistry and Biology, 2003, 10, 1183-1193.	6.2	34
17	The structure ofEnterococcus faecalisthymidylate synthase provides clues about folate bacterial metabolism. Acta Crystallographica Section D: Biological Crystallography, 2012, 68, 1232-1241.	2.5	28
18	Target-based approaches for the discovery of new antimycobacterial drugs. Drug Discovery Today, 2017, 22, 576-584.	3.2	28

#	Article	IF	Citations
19	Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. European Journal of Medicinal Chemistry, 2018, 146, 423-434.	2.6	27
20	Antibacterial Agent Discovery Using Thymidylate Synthase Biolibrary Screening. Journal of Medicinal Chemistry, 2006, 49, 5958-5968.	2.9	24
21	Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery. ACS Omega, 2017, 2, 5666-5683.	1.6	24
22	Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth. Journal of Medicinal Chemistry, 2014, 57, 1355-1367.	2.9	22
23	Hotspots in an Obligate Homodimeric Anticancer Target. Structural and Functional Effects of Interfacial Mutations in Human Thymidylate Synthase. Journal of Medicinal Chemistry, 2015, 58, 3572-3581.	2.9	21
24	Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case. ChemMedChem, 2016, 11, 1653-1666.	1.6	21
25	Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections. Journal of Medicinal Chemistry, 2019, 62, 3989-4012.	2.9	21
26	Inhibitor of Ovarian Cancer Cells Growth by Virtual Screening: A New Thiazole Derivative Targeting Human Thymidylate Synthase. Journal of Medicinal Chemistry, 2012, 55, 10272-10276.	2.9	20
27	Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds. European Journal of Medicinal Chemistry, 2017, 126, 1129-1135.	2.6	20
28	Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase. Journal of Medicinal Chemistry, 2016, 59, 9269-9275.	2.9	19
29	Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics. European Journal of Medicinal Chemistry, 2019, 183, 111676.	2.6	18
30	Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. SLAS Discovery, 2019, 24, 346-361.	1.4	18
31	X-ray crystal structures of Enterococcus faecalis thymidylate synthase with folate binding site inhibitors. European Journal of Medicinal Chemistry, 2016, 123, 649-664.	2.6	17
32	Structural Comparison of Enterococcus faecalis and Human Thymidylate Synthase Complexes with the Substrate dUMP and Its Analogue FdUMP Provides Hints about Enzyme Conformational Variabilities. Molecules, 2019, 24, 1257.	1.7	17
33	Improving Specificity vs Bacterial Thymidylate Synthases throughN-Dansyl Modulation of Didansyltyrosine. Journal of Medicinal Chemistry, 2005, 48, 913-916.	2.9	16
34	Dimerâ€“monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer. Protein Science, 2010, 19, 1023-1030.	3.1	16
35	Aza-boronic acids as non-Î²-lactam inhibitors of AmpC-Î²-lactamase. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3979-3983.	1.0	14
36	Sequenceâ€Based Identification of Specific Drug Target Regions in the Thymidylate Synthase Enzyme Family. ChemMedChem, 2008, 3, 392-401.	1.6	14

#	Article	IF	Citations
37	Synthesis of N-(5,7-diamino-3-phenyl-quinoxalin-2-yl)-3,4,5-substituted anilines and N-[4[(5,7-diamino-3-phenylquinoxalin-2-yl)amino]benzoyl]-l-glutamic acid diethyl ester: Evaluation of in vitro anti-cancer and anti-folate activities. European Journal of Medicinal Chemistry, 2008, 43, 189-203.	2.6	13
38	Identification of the Binding Modes ofN-Phenylphthalimides Inhibiting Bacterial Thymidylate Synthase through X-Ray Crystallography Screening. Journal of Medicinal Chemistry, 2011, 54, 5454-5467.	2.9	13
39	Folic Acidâ€“Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting. Journal of Medicinal Chemistry, 2021, 64, 3204-3221.	2.9	13
40	Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth. Vitamins and Hormones, 2018, 107, 473-513.	0.7	12
41	The structure ofCryptococcus neoformansthymidylate synthase suggests strategies for using target dynamics for species-specific inhibition. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 1320-1334.	2.5	10
42	Biochemical effects of riluzole on Leishmania parasites. Experimental Parasitology, 2013, 133, 250-254.	0.5	10
43	Internalization and Stability of a Thymidylate Synthase Peptide Inhibitor in Ovarian Cancer Cells. Journal of Medicinal Chemistry, 2014, 57, 10551-10556.	2.9	10
44	2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes. European Journal of Medicinal Chemistry, 2014, 75, 169-183.	2.6	9
45	Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 663-668.	1.0	8
46	2â€²-Deoxyuridine 5â€²-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives. Journal of Medicinal Chemistry, 2013, 56, 9356-9360.	2.9	8
47	Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. European Journal of Medicinal Chemistry, 2020, 189, 112047.	2.6	8
48	Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. Frontiers in Pharmacology, 2018, 9, 454.	1.6	7
49	Proteinâ€“Protein Interaction Inhibitors: Case Studies on Small Molecules and Natural Compounds. , 2013, , 31-60.		7
50	Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding. Protein Engineering, Design and Selection, 2010, 23, 81-89.	1.0	6
51	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth. Journal of Medicinal Chemistry, 2018, 61, 7374-7380.	2.9	6
52	SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent. ACS Medicinal Chemistry Letters, 2019, 10, 528-533.	1.3	5
53	A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 4452.	1.8	5
54	Constrained Dansyl Derivatives Reveal Bacterial Specificity of Highly Conserved Thymidylate Synthases. ChemBioChem, 2008, 9, 779-790.	1.3	4

#	Article	IF	Citations
55	Anchors away. Nature, 2009, 458, 840-841.	13.7	4
56	Scaffolds and Biological Targets Avenue to Fight Against Drug Resistance in Leishmaniasis. Annual Reports in Medicinal Chemistry, 2018, 51, 39-95.	0.5	4
57	A step further in the discovery of phthalein derivatives as Thymidylate Synthase inhibitors. Arkivoc, 2004, 2004, 382-396.	0.3	4
58	Targeting the Trypanosomatidic Enzymes Pteridine Reductase and Dihydrofolate Reductase. , 2013, , 445-472.		2
59	Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors. Molecules, 2019, 24, 1362.	1.7	2
60	Structural Bases for the Synergistic Inhibition of Human Thymidylate Synthase and Ovarian Cancer Cell Growth by Drug Combinations. Cancers, 2021, 13, 2061.	1.7	2
61	Intrinsic Fluorescence of the Active and the Inactive Functional Forms of Human Thymidylate Synthase. ChemBioChem, 2021, 22, 1800-1810.	1.3	1
62	Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library. Pharmaceutics, 2022, 14, 391.	2.0	1
63	Intrinsic Fluorometric Reporters of Pteridine Reductase 1, a Target for Antiparasitic Agents. Physchem, 2022, 2, 131-144.	0.5	0